SpringWorks Therapeutics, Inc. (SWTX)

NASDAQ: SWTX · IEX Real-Time Price · USD
30.81
+0.74 (2.46%)
At close: Jan 27, 2023, 4:00 PM
32.00
+1.19 (3.86%)
After-hours: Jan 27, 2023, 5:21 PM EST
2.46%
Market Cap 1.92B
Revenue (ttm) n/a
Net Income (ttm) -259.31M
Shares Out 62.38M
EPS (ttm) -5.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 502,885
Open 29.94
Previous Close 30.07
Day's Range 29.94 - 31.27
52-Week Range 13.60 - 65.92
Beta 0.57
Analysts Buy
Price Target 65.79 (+113.54%)
Earnings Date Feb 23, 2023

About SWTX

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clini... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Mr. Saqib Islam J.D.
Employees 222
Stock Exchange NASDAQ
Ticker Symbol SWTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for SWTX stock is "Buy." The 12-month stock price forecast is $65.79, which is an increase of 113.54% from the latest price.

Price Target
$65.79
(113.54% upside)
Analyst Consensus: Buy
Stock Forecasts

News

SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn., Jan. 09, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...

2 weeks ago - GlobeNewsWire

Kaskela Law LLC Announces Investigation of SpringWorks Therapeutics, Inc. (SWTX) and Encourages Long-Term SWTX Investors to Contact the Firm

Philadelphia, Pennsylvania--(Newsfile Corp. - January 6, 2023) - Kaskela Law LLC announces that it is investigating SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) on behalf of the company's long-term i...

3 weeks ago - Newsfile Corp

SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn., Jan. 03, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...

3 weeks ago - GlobeNewsWire

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors

STAMFORD, Conn., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...

1 month ago - GlobeNewsWire

SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference

STAMFORD, Conn., Nov. 22, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...

2 months ago - GlobeNewsWire

SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

– Presented Positive Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022 –

3 months ago - GlobeNewsWire

Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma

CONCORD, Mass. , Nov. 1, 2022 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelera...

3 months ago - PRNewsWire

Wall Street Analysts Think SpringWorks Therapeutics (SWTX) Could Surge 212%: Read This Before Placing a Bet

The mean of analysts' price targets for SpringWorks Therapeutics (SWTX) points to a 211.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem...

3 months ago - Zacks Investment Research

SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors

STAMFORD, Conn., Sept. 29, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients...

4 months ago - GlobeNewsWire

SpringWorks (SWTX), GSK Expand Deal to Treat Multiple Myeloma

Per the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK's (GSK) development program for its multiple myeloma drug, Blenrep.

5 months ago - Zacks Investment Research

SpringWorks Therapeutics Announces $225 Million Private Placement Financing

Strengthens Financial Position to Over $600 Million in Cash, Cash Equivalents and Marketable Securities, Upon Closing of the Financing Strengthens Financial Position to Over $600 Million in Cash, Cash...

5 months ago - GlobeNewsWire

SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma

- SpringWorks to Receive $75 Million Equity Investment with Potential for an Additional $550 Million in Milestone Payments -

5 months ago - GlobeNewsWire

SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

– Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors Met Its Primary and All Key Secondary Endpoints –

6 months ago - GlobeNewsWire

SpringWorks Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Conference

STAMFORD, Conn., Aug. 02, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...

6 months ago - GlobeNewsWire

SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors

STAMFORD, Conn., July 15, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...

7 months ago - GlobeNewsWire

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in SpringWorks Therapeutics, Inc. with Losses to Contact the Firm

Los Angeles, California--(Newsfile Corp. - June 24, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spri...

7 months ago - Newsfile Corp

SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch

HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week. As per a s...

8 months ago - Benzinga

SpringWorks Therapeutics to Present Progress Across the Company's Targeted Oncology Portfolio at Virtual R&D Day

-- NDA filing for Nirogacestat in Desmoid Tumors, Which Will Be Reviewed Under the FDA's Real-Time Oncology Review (RTOR) Program, Expected in Second Half of 2022 -- -- New Phase 2 Study Announced to ...

8 months ago - GlobeNewsWire

SpringWorks Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

STAMFORD, Conn., June 09, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...

8 months ago - GlobeNewsWire

Here is why SpringWorks Therapeutics jumped 20%

SpringWorks Therapeutics Inc. (NASDAQ: SWTX) stock jumped 20% after the clinical-stage company focusing on life-changing treatment for cancer, and rare diseases announced encouraging results from its ...

8 months ago - Invezz

Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting

The stocks for companies developing cancer therapies were moving in morning trading on Friday as biotechs and researchers shared new clinical findings in advance of next week's American Society of Cli...

Other symbols: ACLXIOVAMRTXZYME
8 months ago - Market Watch

SpringWorks Therapeutics Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting

- Initial Data to be Presented from GSK-Sponsored Phase 1/2 Study Evaluating Nirogacestat in Combination with Low-Dose BLENREP in Patients with Relapsed or Refractory Multiple Myeloma -

8 months ago - GlobeNewsWire

SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal

SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.

8 months ago - Zacks Investment Research

Why SpringWorks Shares Are Soaring Today Premarket

SpringWorks Therapeutics Inc (NASDAQ: SWTX) has announced positive topline results from the DeFi Phase 3 trial evaluating nirogacestat in adult patients with progressing desmoid tumors. Desmoid tumors...

8 months ago - Benzinga

SpringWorks shares jump 14%; company plans to seek FDA approval for desmoid tumor therapy this year

Shares of SpringWorks Therapeutics Inc. SWTX, +2.18% were up 14.9% in premarket trading on Tuesday after the company said a late-stage clinical trial evaluating its treatment for patients with progres...

8 months ago - Market Watch